Ocean Biomedical, Inc. (OCEA)
- Previous Close
1.2550 - Open
1.2600 - Bid 1.3100 x 200
- Ask 1.3600 x 400
- Day's Range
1.2600 - 1.4268 - 52 Week Range
0.5200 - 12.0800 - Volume
246,371 - Avg. Volume
6,805,801 - Market Cap (intraday)
46.43M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.50
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
www.oceanbiomedical.comRecent News: OCEA
Performance Overview: OCEA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCEA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCEA
Valuation Measures
Market Cap
46.43M
Enterprise Value
58.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.72
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-681.99%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-98.59M
Diluted EPS (ttm)
-3.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
31k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.56M